Tumor initiating cells in malignant gliomas: biology and implications for therapy
- 3 February 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Molecular Medicine
- Vol. 87 (4), 363-374
- https://doi.org/10.1007/s00109-009-0440-9
Abstract
A rare subpopulation of cells within malignant gliomas, which shares canonical properties with neural stem cells (NSCs), may be integral to glial tumor development and perpetuation. These cells, also known as tumor initiating cells (TICs), have the ability to self-renew, develop into any cell in the overall tumor population (multipotency), and proliferate. A defining property of TICs is their ability to initiate new tumors in immunocompromised mice with high efficiency. Mounting evidence suggests that TICs originate from the transformation of NSCs and their progenitors. New findings show that TICs may be more resistant to chemotherapy and radiation than the bulk of tumor cells, thereby permitting recurrent tumor formation and accounting for the failure of conventional therapies. The development of new therapeutic strategies selectively targeting TICs while sparing NSCs may provide for more effective treatment of malignant gliomas.Keywords
This publication has 106 references indexed in Scilit:
- CXCR4 mediates the proliferation of glioblastoma progenitor cellsCancer Letters, 2009
- Metallic Iron Nanoparticles for MRI Contrast Enhancement and Local HyperthermiaSmall, 2008
- The interface between glial progenitors and gliomasActa Neuropathologica, 2008
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and InvasionCancer Cell, 2008
- Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating CellsCancer Cell, 2008
- Hypoxia-Inducible Factors, Stem Cells, and CancerCell, 2007
- Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant GliomaNeuron, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and TumorigenicityCurrent Biology, 2007
- The Hallmarks of CancerCell, 2000